瑞博生物-B：超额配股权获悉数行使 稳定价格期结束

Core Viewpoint - The company, 瑞博生物-B (06938), has fully exercised its over-allotment option, involving a total of 4.7414 million H-shares, which represents approximately 15% of the total shares available for subscription prior to the exercise of the over-allotment option [1] Group 1 - The over-allotment shares will be issued at a price of HKD 57.97 per H-share [1] - The over-allotment shares are intended to cover the excess allocation in the international offering [1] - The stabilization period for the global offering ended on February 5, 2026, with no H-shares being traded in the market for stabilization purposes [1]